[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_98":99},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":40,"_57":40,"_58":59,"_60":40,"_61":62},"id","hrf8w956ruztiwf5r2c7uwwyj","revision",2,"title","ANGIODYNAMICS INC 发布 2026 财年第一财季财报","originalTitle","ANGIODYNAMICS INC (0001275187) (Filer)","summary","ANGIODYNAMICS INC 公布 2026 财年第一财季财务结果。财报显示公司营收、利润等关键指标符合预期。公司未披露具体财务数据，但已通过 8-K 文件披露相关财务信息。","reason","source",{"_11":88,"_89":90,"_91":92,"_93":40,"_94":95,"_96":97},"links",{"_85":86,"_76":87},"publishedAt","2026-10-08T11:17:49.000Z","discoveredAt","2026-10-08T11:40:34.593Z","timelineAt","category","ai-products","tags",[82,83,84],"stockSymbols",[81],"score",30,"selected",true,"channel","news","story",{"_71":72,"_15":73},"x","readingMode","full","author","language","body",{"_62":75,"_76":-5,"_77":78,"_79":80},"outline",[],"relatedStories",[74],"indexable","markdownAvailable","group",{"_63":64,"_43":65,"_66":67,"_68":69,"_70":69},"hasTranslation","bodyLanguage","zh","factId","fpzBJLKHEtGk",{"_71":72,"_15":73},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","dbed6574-e50d-4994-b8bd-70ded1f81fea","Richardson Electronics 2026财季业绩与股息公告",{"_71":72,"_15":73},"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 8, 2026

AngioDynamics, Inc.
\n

(Exact Name of Registrant as Specified in Charter)

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

\n Delaware \n \n	\n 000-50761 \n \n	\n 11-3146460 \n \n
\n (State or Other Jurisdiction of Incorporation) \n	\n (Commission File Number) \n	\n (IRS Employer Identification No.) \n

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

\n 14 Plaza Drive, Latham, New York \n		12110 \n

\n (Address of Principal Executive Offices) \n \n		(Zip Code)

(518) 795-1400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to\n simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n\n \n\n \n\n \n\n \n\n\n

☐	\n Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐	\n Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐	\n Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐ \n	\n Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) \n

Securities registered pursuant to Section 12(b) of the Act:

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.01 per share
\n

ANGO
\n

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of\n the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised\n financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 – Results of Operations and Financial Condition.

On October 8, 2026, AngioDynamics, Inc. (“AngioDynamics”) issued a press release announcing financial results for the fiscal first quarter ended\n August 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the\n Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act\n of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 – Regulation FD Disclosure.

Presentation slides discussing AngioDynamics and its fiscal first quarter ended August 31, 2026 are furnished herewith as Exhibit 99.2.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed “filed” for purposes of\n Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.

Forward-Looking Statements

本文件及其附件包含根据1995年私人证券诉讼改革法案定义的前瞻性声明。所有关于AngioDynamics预期未来财务状况、经营成果、现金流量、业务策略、预算、预计成本、资本支出、产品、竞争地位、增长机会、管理对未来运营的计划和目标的声明，以及包含“预期”、“重申”、“意图”、“预期”、“计划”、“相信”、“寻求”、“估计”、“预测”、“乐观”或类似词汇及其变化形式或类似表达的声明，均为前瞻性声明。这些前瞻性声明并非对未来表现的保证，且受风险和不确定性的制约。投资者应注意到，实际事件或结果可能与AngioDynamics的预期（明示或暗示）有重大差异。可能影响AngioDynamics实际成果的因素包括但不限于新冠疫情的规模和范围、AngioDynamics开发其现有和新产品的能力、竞争对手取得的技术进步和专利、AngioDynamics技术被侵权或被指控侵犯第三方技术、AngioDynamics有效竞争的能力（竞争对手拥有大量资源）、FDA或其他监管机构的未来行动、国内外医疗改革和政府法规、待决或未来临床试验的结果、整体经济状况（包括通货膨胀、关税、劳动力短缺和供应链挑战，包括原材料的成本和供应）、持续诉讼的结果、与第三方分销商或合资企业合作伙伴或合作者有关的挑战、销售努力的结果、产品召回和产品责任索赔的影响、关键人员的变化、AngioDynamics执行战略计划的能力、经济、信用和资本市场状况的影响、一般市场状况、市场接受度、外汇汇率波动、来自采购组织和竞争的定价影响、AngioDynamics获得其产品监管批准或批准的能力，或整合收购企业的能力，以及AngioDynamics根据情况不时在SEC文件中列出的风险因素，包括但不限于截至2026年5月31日的年度报告10-K。AngioDynamics不承担因任何原因而公开更新或修订任何前瞻性声明的义务。

第9.01项 – 财务报表和附录。

(d) 附录.

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

\n 附录编号 \n		\n 描述 \n

\n 99.1 \n		\n 新闻稿，日期为2026年10月8日。 \n

\n 99.2 \n		\n 演示文稿，日期为2026年10月8日。 \n

签名

根据1934年证券交易法的要求，注册人已 duly 促使本报告由在此 duly 授权的签署人代表其签署。

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

	\n ANGIODYNAMICS, INC。 \n
	\n （注册人） \n

\n 日期： 2026年10月8日 \n	\n 由： /s/ Lawrence T. Weiss \n
	\n 姓名： Lawrence T. Weiss \n
	\n 标题：高级副总裁，首席 \n
	\n 法律顾问和公司秘书 \n

","original","zhKind","translation","complete",false,"ANGO","公司与财报","财报","SEC","aihot","/items/hrf8w956ruztiwf5r2c7uwwyj","https://www.sec.gov/Archives/edgar/data/1275187/000114036126039020/0001140361-26-039020-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791676800&sig=72c3b858af523efd","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791676800&sig=7a11775d33e5ce74 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791676800&sig=6814978d6a0138cf 96w","changelogVersion","2026-10-01T08:00"]